Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

TRILOGY 2 study of CaPre in severe hypertriglyceridemia does not meet primary endpoint

Aug. 31, 2020

Cyprium reports topline clinical data for CUTX-101 in Menkes disease

Aug. 31, 2020

Preclinical results suggest erectile dysfunction drugs can be repurposed to treat osteoporosis

Aug. 31, 2020

Roche reports the discovery of novel CYP11B2 inhibitors

Aug. 25, 2020

Islet organoids can evade immune attack

Aug. 24, 2020

Bristol-Myers Squibb identifies MGAT2 inhibitors for metabolic disorders

Aug. 24, 2020

Enrollment ongoing in phase I study of ZF-874

Aug. 20, 2020

Mice and men and estrogen

Aug. 18, 2020

Low-dose IL-2 shows potential for treating children with type 1 diabetes

Aug. 12, 2020

SCO-094 enters phase I testing in patients with type 2 diabetes mellitus

Aug. 12, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...